[A22-58] Pembrolizumab (endometrial carcinoma) - Addendum to Commission A21-164
Last updated 07.07.2022
Commission awarded on 24.05.2022 by the Federal Joint Committee (G-BA).
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
|A21-164||Pembrolizumab (endometrial carcinoma) - Benefit assessment according to §35a Social Code Book V||Commission completed|
Federal Joint Committee (G-BA)
2022-07-07 A G-BA decision was published.
G-BA documents on this decision